Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.
Covered in this story
Call it yourself
No calls on $ANVS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Annovis Bio →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.